Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Resverlogix Announces Presentations at Leading Scientific Conferences

GlobeNewswire October 15, 2020

Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet

GlobeNewswire October 14, 2020

Zenith Provides Update Regarding Extension of its Filing Calendar

GlobeNewswire October 9, 2020

Resverlogix Announces $13 Million Private Placement

GlobeNewswire October 6, 2020

Resverlogix Confirms Interim Filings on SEDAR

GlobeNewswire October 2, 2020

Resverlogix Provides Update Regarding Extension of its Filing Calendar

GlobeNewswire September 25, 2020

Resverlogix Announces Publication in High-impact Peer-reviewed Journal - Medicinal Research Reviews

GlobeNewswire September 15, 2020

Resverlogix Provides Update Regarding Extension of its Filing Calendar

GlobeNewswire September 11, 2020

Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum ("GCFF") Virtual Conference 2020 - Investing in Innovation

GlobeNewswire September 8, 2020

Resverlogix Provides Update Regarding Extension of its Filing Calendar

GlobeNewswire August 28, 2020

Zenith Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

GlobeNewswire August 26, 2020

Resverlogix Announces Private Placement

GlobeNewswire August 14, 2020

Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics

GlobeNewswire August 4, 2020

Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs

GlobeNewswire July 29, 2020

Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

GlobeNewswire July 28, 2020

Resverlogix Secures One-Year Extension of Maturity Date of Debenture

GlobeNewswire July 22, 2020

Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study

GlobeNewswire June 22, 2020

Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment

GlobeNewswire June 16, 2020

Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress

GlobeNewswire June 9, 2020

Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020

GlobeNewswire June 5, 2020